Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension

Clinical Cardiology
J KarlssonH Melhus

Abstract

Studies suggest that the Ser49Gly and Arg389Gly polymorphisms in the beta1-adrenergic receptor might be of functional importance for the cardiovascular system. Both have been associated with altered receptor activity in vitro, and with hypertension and cardiac failure in vivo. The aim of this study was to test whether these polymorphisms were associated with the change in heart rate or blood pressure in patients with essential hypertension and left ventricular (LV) hypertrophy treated with the beta1-adrenergic receptor blocker atenolol. Blood pressure and heart rate were measured in 101 hypertensive patients with echocardiographically verified LV hypertrophy, randomized in a double-blind study to treatment with either the beta1-adrenergic receptor blocker atenolol or the angiotensin II type I receptor antagonist irbesartan. Changes in blood pressure and heart rate were evaluated after 12 weeks. Beta1-adrenergic receptor genotyping was performed using polymerase chain reaction and restriction fragment length polymorphism. We found no significant associations between the changes in the measured variables and either of the two polymorphisms. However, carriers of the 49Gly allele showed a tendency toward a greater reduction in hear...Continue Reading

References

Jan 1, 1994·Annual Review of Biochemistry·C D StraderR A Dixon
Jul 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·D K RohrerB K Kobilka
Apr 23, 1999·The Journal of Biological Chemistry·D A MasonS B Liggett
Jun 8, 1999·The Journal of Biological Chemistry·D K RohrerB K Kobilka
Jun 9, 1999·Proceedings of the National Academy of Sciences of the United States of America·S EngelhardtM J Lohse
Jun 14, 2001·Journal of Hypertension·K MalmqvistJ Ostergern
Oct 11, 2001·Journal of Hypertension·L KurlandUNKNOWN Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) Trial
Jan 16, 2002·Journal of Cardiovascular Pharmacology·Deborah A RathzStephen B Liggett
Feb 21, 2002·American Journal of Human Genetics·Koustubh RanadeNeil Risch

❮ Previous
Next ❯

Citations

Mar 10, 2007·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Ming YuanToshio Ogihara
Nov 27, 2008·Journal of Cardiovascular Pharmacology·Koratagere Nagaraju Mahesh KumarChandrasekaran Adithan
Jul 11, 2008·Clinical Pharmacology and Therapeutics·M A PacanowskiUNKNOWN INVEST Investigators
Dec 17, 2008·Pharmacological Reviews·Dieter Rosskopf, Martin C Michel
Mar 10, 2011·Journal of Cardiovascular Pharmacology·Henk VisscherBruce C Carleton
Mar 23, 2011·Journal of Pharmacological Sciences·Toshiyuki SasaguriSachio Morimoto
May 5, 2012·Scottish Medical Journal·H L Huang, K A A Fox
Dec 14, 2012·Expert Review of Clinical Pharmacology·Murielle Bochud, Idris Guessous
Oct 12, 2013·Annual Review of Medicine·Peter Weeke, Dan M Roden
Feb 27, 2018·Journal of the American Heart Association·Mohamed H ShahinJulie A Johnson
Nov 1, 2007·Personalized Medicine·Jean-Brice MarteauSophie Visvikis-Siest
Jun 9, 2005·Journal of Hypertension·Philip B Mellen, David M Herrington
Apr 26, 2006·The Pharmacogenomics Journal·M R G Taylor
Jul 25, 2006·Expert Opinion on Pharmacotherapy·Issam Zineh, Julie A Johnson
Aug 12, 2009·Pharmacogenomics·Donna K Arnett, Steven A Claas
Jun 5, 2007·Pharmacotherapy·Jaekyu Shin, Julie A Johnson
Jan 19, 2012·Anaesthesia·R LandauJ C Kraft
Sep 8, 2010·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Michael KindermannChristoph Maack
May 25, 2012·Expert Opinion on Drug Metabolism & Toxicology·Sze Wa ChanBrian Tomlinson
Jun 15, 2014·Pharmacological Reviews·Andrea Ahles, Stefan Engelhardt
Nov 26, 2015·Nature Reviews. Nephrology·Rhonda M Cooper-DeHoff, Julie A Johnson
Apr 1, 2015·The Journal of International Medical Research·Dingchang WuJiasen Xu
Jun 8, 2017·International Journal of Molecular Sciences·Jacopo BurrelloPaolo Mulatero
Aug 10, 2017·Expert Opinion on Drug Metabolism & Toxicology·Elliot Berinstein, Andrew Levy
Nov 5, 2005·Journal of Hypertension·Jean-Brice MarteauSophie Visvikis-Siest
Mar 21, 2008·Fundamental & Clinical Pharmacology·Otto-Erich Brodde
Apr 13, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Vincent Lai Ming Yip, Munir Pirmohamed
Sep 12, 2009·Clinical Chemistry and Laboratory Medicine : CCLM·Yingxin PengRongbin Li
May 22, 2013·Current Cardiology Reports·Peter Weeke, Dan M Roden
May 16, 2019·Journal of Clinical Pharmacology·Mohamed H ShahinJulie A Johnson
Jan 31, 2007·Naunyn-Schmiedeberg's Archives of Pharmacology·Dieter RosskopfRafael Schäfers
Sep 10, 2017·Physiological Genomics·Amy L PasternakDaniel L Hertz
Jul 30, 2020·Expert Opinion on Drug Metabolism & Toxicology·Cameron D Thomas, Julie A Johnson
Mar 26, 2008·Exercise and Sport Sciences Reviews·Eric M SnyderMichael J Joyner
Aug 2, 2011·European Heart Journal·Jeffrey J W VerschurenJ Wouter Jukema

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.